{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:12:47Z","timestamp":1792843967934,"version":"4.5.0"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Chikungunya virus (CHIKV), a single-stranded RNA virus transmitted by Aedes mosquitoes, poses a significant global health threat, with severe complications observed in vulnerable populations. The only licensed vaccine, IXCHIQ, approved by the US FDA, is insufficient to address the growing disease burden, particularly in endemic regions lacking herd immunity. Monoclonal antibodies (mAbs), explicitly targeting structural proteins E1\/E2, demonstrate promise in passive transfer studies, with mouse and human-derived mAbs showing protective efficacy. This article explores various vaccine candidates, including live attenuated, killed, nucleic acid-based (DNA\/RNA), virus-like particle, chimeric, subunit, and adenovirus vectored vaccines. RNA vaccines have emerged as promising candidates due to their rapid response capabilities and enhanced safety profile. This review underscores the importance of the E1 and E2 proteins as immunogens, emphasizing their antigenic potential. Several vaccine candidates, such as CHIKV\/IRES, measles vector (MV-CHIK), synthetic DNA-encoded antibodies, and mRNA-lipid nanoparticle vaccines, demonstrate encouraging preclinical and clinical results. In addition to identifying potential molecular targets for antiviral therapy, the study looks into the roles played by Toll-like receptors, RIG-I, and NOD-like receptors in the immune response to CHIKV. It also offers insights into novel tactics and promising vaccine candidates. This article discusses potential antiviral targets, the significance of E1 and E2 proteins, monoclonal antibodies, and RNA vaccines as prospective Chikungunya virus vaccine candidates.<\/jats:p>","DOI":"10.3389\/fmicb.2024.1413250","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T05:29:17Z","timestamp":1721626157000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions"],"prefix":"10.3389","volume":"15","author":[{"given":"Mohd Sayeed","family":"Shaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md.","family":"Faiyazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubasshera Sabir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz K.","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran J.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol D.","family":"Gholap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shabib","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjit","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Katterine","family":"Bonilla-Aldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso J.","family":"Rodriguez-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7010002","article-title":"Attenuation and stability of chikv-nols, a live-attenuated chikungunya virus vaccine candidate","author":"Abeyratne","year":"2019","journal-title":"Vaccine"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fimmu.2020.00304","article-title":"Liposomal delivery of the RNA genome of a live-attenuated chikungunya virus vaccine candidate provides local, but not systemic protection after one dose","volume":"11","author":"Abeyratne","year":"2020","journal-title":"Front. Immunol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"8879","DOI":"10.1128\/jvi.00370-12","article-title":"A specific domain of the chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus Vaccine design","volume":"86","author":"Akahata","year":"2012","journal-title":"J. Virol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat. Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S1473-3099(15)70160-X","article-title":"Chikungunya, the emerging migratory rheumatism","volume":"15","author":"Alfaro-Toloza","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.12688\/f1000research.11078.2","article-title":"Cardiovascular involvement and manifestations of systemic chikungunya virus infection: A systematic review","volume":"6","author":"Alvarez","year":"2017","journal-title":"F1000Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/1389201020666191112161743","article-title":"Prediction of epitope-based peptide vaccine against the chikungunya virus by immuno-informatics approach","volume":"21","author":"Anwar","year":"2019","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/0971-5916.155570","article-title":"Envelope specific T cell responses & cytokine profiles in chikungunya patients hospitalized with different clinical presentations","volume":"141","author":"Arankalle","year":"2015","journal-title":"Indian J. Med. Res."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0007316","DOI":"10.1371\/journal.pntd.0007316","article-title":"Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice","volume":"13","author":"Ar\u00e9valo","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"100269","DOI":"10.1016\/j.lansea.2023.100269","article-title":"Cytokine profile, neutralisation potential and viral replication dynamics in sera of chikungunya patients in India: a cross-sectional study","volume":"19","author":"Babu","year":"2023","journal-title":"Lancet Reg. Heal."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41572-023-00429-2","article-title":"Chikungunya fever","volume":"9","author":"Bartholomeeusen","year":"2023","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1128\/9781555815561","volume-title":"Cellular signaling and innate immune responses to RNA virus infections","author":"Brasier","year":"2008"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3390\/v15081707","article-title":"Seroprevalence of IgG antibodies directed against dengue, chikungunya and West Nile viruses and associated risk factors in Madagascar, 2011 to 2013","volume":"15","author":"Broban","year":"2023","journal-title":"Viruses"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3389\/fimmu.2019.02563","article-title":"Vaccine-induced skewing of t cell responses protects against chikungunya virus disease","volume":"10","author":"Broeckel","year":"2019","journal-title":"Front. Immunol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4049\/jimmunol.1401833","article-title":"CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice","volume":"194","author":"Burrack","year":"2015","journal-title":"J. Immunol."},{"key":"ref18","volume-title":"Valneva single \u2013 dose chikungunya vaccine poised to \u2018revolutionize\u2019 global health","author":"Cameron","year":"2023"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"8159","DOI":"10.1371\/journal.pntd.0008159","article-title":"A comparative analysis of the 2007 and 2017 Italian chikungunya outbreaks and implication for public health response","volume":"14","author":"Caputo","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.microb.2023.100018","article-title":"An overview of anti-chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelope","volume":"1","author":"Chandley","year":"2023","journal-title":"Microbe"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jama.2020.2477","article-title":"Effect of a chikungunya virus-like particle Vaccine on safety and tolerability outcomes: A randomized clinical trial","volume":"323","author":"Chen","year":"2020","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41541-023-00722-x","article-title":"Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need","volume":"8","author":"Cherian","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref24","volume-title":"IXCHIQ Chikungunya Vaccine Live IXCHIQ\u00ae Chikungunya Vaccine Live (VLA1553)","year":"2023"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/pathogens9060415","article-title":"Cytokines and chemokines in chikungunya virus infection: protection or induction of pathology","volume":"9","author":"Chirathaworn","year":"2020","journal-title":"Pathogens"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3349\/ymj.2008.49.5.828","article-title":"Expression and evaluation of chikungunya virus E1 and E2 envelope proteins for serodiagnosis of chikungunya virus infection","volume":"49","author":"Cho","year":"2008","journal-title":"Yonsei Med. J."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/infdis\/jiq042","article-title":"Persistent arthralgia induced by chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor","volume":"203","author":"Chow","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1016\/j.vaccine.2013.05.059","article-title":"Deciphering the protective role of adaptive immunity to CHIKV\/IRES a novel candidate vaccine against chikungunya in the A129 mouse model","volume":"31","author":"Chu","year":"2013","journal-title":"Vaccine"},{"key":"ref29","year":"2023"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"40029","DOI":"10.1371\/journal.ppat.0040029","article-title":"A mouse model for chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease","volume":"4","author":"Couderc","year":"2008","journal-title":"PLoS Pathog."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/v14081839","article-title":"Chikungunya virus E2 structural protein B-cell epitopes analysis","volume":"14","author":"da Cruz Silva","year":"2022","journal-title":"Viruses"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.virusres.2018.08.011","article-title":"Characterization of the immune response following in vitro Mayaro and chikungunya viruses (alphavirus, Togaviridae) infection of mononuclear cells","volume":"256","author":"Danillo Lucas Alves","year":"2018","journal-title":"Virus Res."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/jvi.02036-19","article-title":"Chikungunya virus evades antiviral CD8 + T cell responses to establish persistent infection in joint-associated tissues","volume":"94","author":"Davenport","year":"2020","journal-title":"J. Virol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1002\/art.20302","article-title":"Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice","volume":"50","author":"De Hooge","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/v14050969","article-title":"A Review on chikungunya virus epidemiology, pathogenesis and current Vaccine development","volume":"14","author":"de Lima Cavalcanti","year":"2022","journal-title":"Viruses"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/imm.12992","article-title":"Human CD8 T-cell activation in acute and chronic chikungunya infection","volume":"155","author":"de Sousa Dias","year":"2018","journal-title":"Immunology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e92813","DOI":"10.1371\/journal.pone.0092813","article-title":"Characterization of chikungunya virus induced host response in a mouse model of viral myositis","volume":"9","author":"Dhanwani","year":"2014","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"102789","DOI":"10.1016\/j.autrev.2021.102789","article-title":"Chikungunya virus and autoimmunity: consensus immune epitope analysis between chikungunya virus and arthritis","volume":"20","author":"Ding","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref41","volume-title":"Valneva wins race, gaining FDA approval for chikungunya vaccine Ixchiq","author":"Dunleavy","year":"2023"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"S488","DOI":"10.1093\/infdis\/jiw271","article-title":"Development of vaccines for chikungunya fever","volume":"214","author":"Erasmus","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1086\/605496","article-title":"Chikungunya fever: an epidemiological review of a re-emerging infectious disease","volume":"49","author":"Erin Staples","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.1016\/j.vaccine.2022.06.008","article-title":"Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: standardized template with key considerations for a risk\/benefit assessment","volume":"40","author":"Folegatti","year":"2022","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12879-016-1417-2","article-title":"Co-distribution and co-infection of chikungunya and dengue viruses","volume":"16","author":"Furuya-Kanamori","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"ref46","first-page":"25","article-title":"Signal transducer and activator of transcription 1 (STAT1) in inflammatory myopathies","volume":"3","author":"Gallardo","year":"1999","journal-title":"Acta Myol."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.3389\/fmicb.2019.02881","article-title":"Recent Progress in Vaccine development against chikungunya virus","volume":"10","author":"Gao","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.virs.2022.01.032","article-title":"An mRNA vaccine encoding chikungunya virus E2-E1 protein elicits robust neutralising antibody responses and CTL immune responses","volume":"37","author":"Ge","year":"2022","journal-title":"Virol. Sin."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1371\/journal.pmed.0050060","article-title":"Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La R\u00e9union","volume":"5","author":"G\u00e9rardin","year":"2008","journal-title":"PLoS Med."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1471-2334-8-99","article-title":"Estimating chikungunya prevalence in La R\u00e9union Island outbreak by serosurveys: two methods for two critical times of the epidemic","volume":"8","author":"G\u00e9rardin","year":"2008","journal-title":"BMC Infect. Dis."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14760584.2019.1562908","article-title":"Measles-vectored vaccine approaches against viral infections: a focus on chikungunya","volume":"18","author":"Gerke","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"104927","DOI":"10.1016\/j.micinf.2021.104927","article-title":"Regulatory T cells in acute and chronic human chikungunya infection","volume":"24","author":"Gois","year":"2022","journal-title":"Microbes Infect."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.virol.2023.06.001","article-title":"Dual pattern recognition receptor ligands CL401, CL413, and CL429 as adjuvants for inactivated chikungunya virus","volume":"585","author":"Gosavi","year":"2023","journal-title":"Virology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/v15010048","article-title":"Understanding the biology and immune pathogenesis of chikungunya virus infection for Diagnostic and Vaccine development","volume":"15","author":"Hakim","year":"2023","journal-title":"Viruses"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4049\/jimmunol.107.3.643","article-title":"Production and evaluation of a formalin-killed chikungunya Vaccine","volume":"107","author":"Harrison","year":"1971","journal-title":"J. Immunol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.aogh.2016.04.175","article-title":"Characterization of immune factors of chronic chikungunya disease in Grenada, West Indies","volume":"82","author":"Heath","year":"2016","journal-title":"Ann. Glob. Heal."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"49804","DOI":"10.1242\/dmm.049804","article-title":"Evolution and immunopathology of chikungunya virus informs therapeutic development","volume":"16","author":"Henderson Sousa","year":"2023","journal-title":"DMM"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.5772\/24116","article-title":"Arthrogenic alphaviruses and inflammatory myopathies","author":"Herrero","year":"2011","journal-title":"Idiopathic Inflamm. Myopathies Recent Dev."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1016\/j.vaccine.2011.03.089","article-title":"Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection","volume":"29","author":"Holzer","year":"2011","journal-title":"Vaccine"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/d41573-023-00201-x","article-title":"FDA approves first chikungunya vaccine","volume":"23","author":"Idse","year":"2023","journal-title":"Drug Discovery"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"107462","DOI":"10.1016\/j.compbiolchem.2021.107462","article-title":"Computational analysis revealed miRNAs produced by chikungunya virus target genes associated with antiviral immune responses and cell cycle regulation","volume":"92","author":"Islam","year":"2021","journal-title":"Comput. Biol. Chem."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3390\/vaccines10091476","article-title":"mRNA Vaccine designing using chikungunya virus E glycoprotein through Immunoinformatics-guided approaches","volume":"10","author":"Jaan","year":"2022","journal-title":"Vaccine"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2174\/1871526519666190521100521","article-title":"In silico T-cell and B-cell epitope based Vaccine design against alphavirus strain of chikungunya","volume":"20","author":"Jadoon","year":"2019","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2217\/fvl-2019-0166","article-title":"An overview of chikungunya virus molecular biology, epidemiology, pathogenesis, treatment and prevention strategies","volume":"17","author":"Javaid","year":"2022","journal-title":"Future Virol."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.celrep.2015.11.043","article-title":"Neutralizing monoclonal antibodies Block chikungunya virus entry and release by targeting an epitope critical to viral pathogenesis","volume":"13","author":"Jin","year":"2015","journal-title":"Cell Rep."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/ard.2003.013276","article-title":"Activation of the STAT1 pathway in rheumatoid arthritis","volume":"63","author":"Kasperkovitz","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.virusres.2012.05.004","article-title":"Subunit vaccine formulations based on recombinant envelope proteins of chikungunya virus elicit balanced Th1\/Th2 response and virus-neutralizing antibodies in mice","volume":"167","author":"Khan","year":"2012","journal-title":"Virus Res."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12250-019-00135-y","article-title":"Development of a specific CHIKV-E2 monoclonal antibody for chikungunya diagnosis","volume":"34","author":"Kim","year":"2019","journal-title":"Virol. Sin."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40005-015-0205-0","article-title":"In silico prediction of epitopes for chikungunya viral strains","volume":"45","author":"Kori","year":"2015","journal-title":"J. Pharm. Investig."},{"key":"ref70","first-page":"26","article-title":"Burden of chikungunya in India: estimates of disability adjusted life years (DALY) lost in 2006 epidemic","volume":"46","author":"Krishnamoorthy","year":"2009","journal-title":"J. Vector Borne Dis."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"591885","DOI":"10.3389\/fimmu.2020.591885","article-title":"Adenoviral-vectored Mayaro and chikungunya virus Vaccine candidates afford partial Cross-protection from lethal challenge in A129 mouse model","volume":"11","author":"Kroon Campos","year":"2020","journal-title":"Front. Immunol."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1016\/j.vaccine.2012.07.072","article-title":"Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus","volume":"30","author":"Kumar","year":"2012","journal-title":"Vaccine"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1743-422X-9-114","article-title":"Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the chikungunya virus in BEAS-2B cells","volume":"9","author":"Li","year":"2012","journal-title":"Virol. J."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1129118","DOI":"10.3389\/fimmu.2023.1129118","article-title":"Construction and immunogenicity of an mRNA vaccine against chikungunya virus","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"e0028922","DOI":"10.1128\/mbio.00289-22","article-title":"Interleukin-17 contributes to chikungunya virus-induced disease","volume":"13","author":"Liu","year":"2022","journal-title":"MBio"},{"key":"ref17","volume-title":"FDA approves a live, attenuated chikungunya vaccine using accelerated approval","author":"Lucey","year":"2023"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1073\/pnas.94.5.1931","article-title":"Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis","volume":"94","author":"Mach","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/v14020242","article-title":"Current understanding of the role of T cells in chikungunya, dengue and Zika infections","volume":"14","author":"Mapalagamage","year":"2022","journal-title":"Viruses"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.virol.2014.05.038","article-title":"Monoclonal antibody targeting chikungunya virus envelope one protein inhibits virus release","author":"Masrinoul","year":"2014","journal-title":"Virology"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000025023","article-title":"An arthrogenic alphavirus induces monocyte chemoattractant protein-1 and interleukin-8","volume":"43","author":"Mateo","year":"2000","journal-title":"Intervirology"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/v11020175","article-title":"Tropism of the chikungunya virus","volume":"11","author":"Matusali","year":"2019","journal-title":"Viruses"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"e1008292","DOI":"10.1371\/journal.ppat.1008292","article-title":"MyD88-dependent influx of monocytes and neutrophils impairs lymph node B cell responses to chikungunya virus infection via Irf5, Nos2 and Nox2","volume":"16","author":"McCarthy","year":"2020","journal-title":"PLoS Pathog."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11908-023-00811-x","article-title":"New vaccines on the immediate horizon for travelers: chikungunya and dengue vaccines","volume":"25","author":"Menon","year":"2023","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"e2124","DOI":"10.1371\/journal.pntd.0002124","article-title":"Effective chikungunya virus-like particle Vaccine produced in insect cells","volume":"7","author":"Metz","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3390\/vaccines11030568","article-title":"Chikungunya virus: priority pathogen or passing trend?","volume":"11","author":"Montalvo Zurbia-Flores","year":"2023","journal-title":"Vaccine"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11908-022-00789-y","article-title":"Chikungunya: an emerging public health concern","volume":"24","author":"Mourad","year":"2022","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1099\/JGV.0.001629","article-title":"Targeting cap-dependent translation to inhibit chikungunya virus replication: selectivity of p38 MAPK inhibitors to virus-infected cells due to autophagy-mediated down regulation of phospho-ERK","volume":"102","author":"Mudaliar","year":"2021","journal-title":"J. Gen. Virol."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/j.nmd.2017.06.239","article-title":"Inflammatory myopathy related to chikungunya virus: a case report","volume":"27","author":"Muelas","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijid.2016.02.432","article-title":"Synthetic DNA encoded antibody prophylaxis confers rapid protective immunity in vivo against chikungunya virus infection","volume":"45","author":"Muthumani","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1016\/j.vaccine.2008.03.060","article-title":"Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus","volume":"26","author":"Muthumani","year":"2008","journal-title":"Vaccine"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1371\/journal.pone.0004261","article-title":"IL-1\u03b2, IL-6, and RANTES as biomarkers of chikungunya severity","volume":"4","author":"Ng","year":"2009","journal-title":"PLoS One"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1089\/vim.2019.0064","article-title":"Proinflammatory cytokines and chemokines as biomarkers of persistent arthralgia and severe disease after chikungunya virus infection: A 5-year follow-up study in southern Thailand","volume":"32","author":"Ninla-Aesong","year":"2019","journal-title":"Viral Immunol."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1152\/ajpregu.00738.2001","article-title":"Chemokines and chemokine receptors in leukocyte trafficking","volume":"283","author":"Olson","year":"2002","journal-title":"Am. J. Physiol."},{"key":"ref93","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12941-016-0157-x","article-title":"ChikDenMaZika syndrome: the challenge of diagnosing arboviral infections in the midst of concurrent epidemics","volume":"15","author":"Paniz-Mondolfi","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref94","first-page":"1","volume-title":"FDA Grants accelerated approval to chikungunya Vaccine Ixchiq","author":"Park","year":"2010"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1016\/j.vaccine.2012.04.099","article-title":"Cross-protective immunity against o\u2019nyong-nyong virus afforded by a novel recombinant chikungunya vaccine","volume":"30","author":"Partidos","year":"2012","journal-title":"Vaccine"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.micinf.2011.12.008","article-title":"Expression profile of immune response genes during acute myopathy induced by chikungunya virus in a mouse model","volume":"14","author":"Patil","year":"2012","journal-title":"Microbes Infect."},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s10096-020-03933-5","article-title":"Standardization of ELISA for anti-chikungunya-IgG antibodies and age-stratified prevalence of anti-chikungunya-IgG antibodies in Pune, India","volume":"39","author":"Patil","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref98","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12688\/f1000research.7171.1","article-title":"Chikungunya: epidemiology","volume":"5","author":"Petersen","year":"2016","journal-title":"F1000 Faculty Rev."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"e1002142","DOI":"10.1371\/journal.ppat.1002142","article-title":"Novel chikungunya vaccine candidate with an ires-based attenuation and host range alteration mechanism","volume":"7","author":"Plante","year":"2011","journal-title":"PLoS Pathog."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type i IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther."},{"key":"ref101","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1128\/CMR.00104-16","article-title":"Vaccine and therapeutic options to control chikungunya virus","volume":"31","author":"Powers","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.meegid.2013.09.030","article-title":"Differential regulation of TLR mediated innate immune response of mouse neuronal cells following infection with novel ECSA genotype of chikungunya virus with and without E1: A226V mutation","volume":"20","author":"Priya","year":"2013","journal-title":"Infect. Genet. Evol."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.virusres.2014.05.010","article-title":"TLR3 mediated innate immune response in mice brain following infection with chikungunya virus","volume":"189","author":"Priya","year":"2014","journal-title":"Virus Res."},{"key":"ref104","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2807\/ese.13.07.08039-en","article-title":"Excess mortality as an epidemic intelligence tool in chikungunya mapping","volume":"13","author":"Ramchurn","year":"2008","journal-title":"Euro Surveill."},{"key":"ref105","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2018.11.291","article-title":"Phase 2 clinical results: chikungunya vaccine based on measles vector (MV-CHIK) induces humoral and cellular responses in the presence of pre-existing anti-measles immunity","volume":"79","author":"Ramsauer","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref106","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: A randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"S500","DOI":"10.1093\/infdis\/jiw369","article-title":"Chikungunya virus vaccines: viral vector-based approaches","volume":"214","author":"Ramsauer","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/jmv.23875","article-title":"Correlation of plasma viral loads and presence of chikungunya IgM antibodies with cytokine\/chemokine levels during acute chikungunya virus infection","volume":"86","author":"Reddy","year":"2014","journal-title":"J. Med. Virol."},{"key":"ref109","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2018","journal-title":"Lancet"},{"key":"ref110","first-page":"51","article-title":"Role of cytokines, chemokines, C3a, and mannose-binding lectin in the evolution of the chikungunya infection","volume":"11","author":"Restrepo","year":"2022","journal-title":"Am. J. Clin. Exp. Immunol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(07)61779-6","article-title":"Infection with chikungunya virus in Italy: an outbreak in a temperate region","volume":"370","author":"Rezza","year":"2007","journal-title":"Lancet"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"e0006919","DOI":"10.1371\/journal.pntd.0006919","article-title":"Chikungunya as a paradigm for emerging viral diseases: evaluating disease impact and hurdles to vaccine development","volume":"13","author":"Rezza","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref113","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref114","volume-title":"Summary basis for regulatory action","author":"Robert","year":"2023"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"12252","DOI":"10.1128\/jvi.77.22.12252-12265.2003","article-title":"Gamma interferon is critical for neuronal viral clearance and protection in a susceptible mouse strain following early intracranial Theiler\u2019s murine encephalomyelitis virus infection","volume":"77","author":"Rodriguez","year":"2003","journal-title":"J. Virol."},{"key":"ref116","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/v14010070","article-title":"Genetic diversity and spatiotemporal dynamics of chikungunya infections in Mexico during the outbreak of 2014\u20132016","volume":"14","author":"Rodr\u00edguez-Aguilar","year":"2022","journal-title":"Viruses"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00296-015-3302-5","article-title":"How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America?","volume":"35","author":"Rodriguez-Morales","year":"2015","journal-title":"Rheumatol. Int."},{"key":"ref118","doi-asserted-by":"publisher","first-page":"360","DOI":"10.12688\/f1000research.8235.2","article-title":"Post-chikungunya chronic inflammatory rheumatism: Results from a retrospective follow-up study of 283 adult and child cases in La Virginia, Risaralda, Colombia","volume":"5","author":"Rodriguez-Morales","year":"2016","journal-title":"F1000Res"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12932\/ap-271222-1520","article-title":"Chikungunya vaccines: an update in 2023","volume":"41","author":"Roongaraya","year":"2023","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref120","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/art.24682","article-title":"Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins","volume":"60","author":"Rulli","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref121","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/infdis\/jir470","article-title":"Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis","volume":"204","author":"Rulli","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref122","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.vaccine.2008.11.013","article-title":"The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na\u00efve recipient mice","volume":"27","author":"Salem","year":"2009","journal-title":"Vaccine"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.omtn.2022.04.036","article-title":"A taRNA vaccine candidate induces a specific immune response that protects mice against chikungunya virus infections","volume":"28","author":"Schmidt","year":"","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"ref124","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.3390\/vaccines10091374","article-title":"A bivalent trans-amplifying RNA Vaccine candidate induces potent chikungunya and Ross River virus specific immune responses","volume":"10","author":"Schmidt","year":"","journal-title":"Vaccine"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3389\/fimmu.2020.00592","article-title":"Current efforts in the development of vaccines for the prevention of Zika and chikungunya virus infections","volume":"11","author":"Schrauf","year":"2020","journal-title":"Front. Immunol."},{"key":"ref127","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/cells12040556","article-title":"Chikungunya virus and its envelope protein E2 induce hyperalgesia in mice: inhibition by anti-E2 monoclonal antibodies and by targeting TRPV1","volume":"12","author":"Segato-Vendrameto","year":"2023","journal-title":"Cells"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijid.2018.11.058","article-title":"Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial","volume":"79","author":"Shaw","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref129","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/jtm\/taad008","article-title":"Chikungunya: risks for travellers","volume":"30","author":"Simon","year":"2023","journal-title":"J. Travel Med."},{"key":"ref130","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1371\/journal.pntd.0000389","article-title":"Post-epidemic chikungunya disease on Reunion island: course of rheumatic manifestations and associated factors over a 15-month period","volume":"3","author":"Sissoko","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref131","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1086\/317537","article-title":"Type 1\/type 2 immunity in infectious diseases","volume":"32","author":"Spellberg","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref132","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.4269\/ajtmh.17-0762","article-title":"The burden of dengue fever and chikungunya in southern coastal Ecuador: epidemiology, clinical presentation, and phylogenetics from the first two years of a prospective study","volume":"98","author":"Stewart-Ibarra","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref133","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.4049\/jimmunol.164.12.6593","article-title":"Increased CD40 expression on muscle cells of Polymyositis and Dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant Protein-1 production","volume":"164","author":"Sugiura","year":"2000","journal-title":"J. Immunol."},{"key":"ref134","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/trstmh\/trz065","article-title":"Cytokines and chemokines triggered by chikungunya virus infection in human patients during the very early acute phase","volume":"113","author":"Tanabe","year":"2019","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref136","doi-asserted-by":"publisher","first-page":"121","DOI":"10.15252\/emmm.201707885","article-title":"Co-infection with chikungunya virus alters trafficking of pathogenic CD 8 + T cells into the brain and prevents plasmodium \u2013induced neuropathology","volume":"10","author":"Teo","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref137","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1016\/j.vaccine.2022.04.021","article-title":"Immunological implications of diverse production approaches for chikungunya virus-like particle vaccines","volume":"40","author":"Thompson","year":"2022","journal-title":"Vaccine"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.vaccine.2022.11.028","article-title":"Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling","volume":"41","author":"Tran","year":"2023","journal-title":"Vaccine"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00253-022-12280-8","article-title":"Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells","volume":"107","author":"Tsai","year":"2023","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref140","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.coviro.2016.02.007","article-title":"Interspecies transmission and chikungunya virus emergence","volume":"16","author":"Tsetsarkin","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref141","doi-asserted-by":"publisher","first-page":"e1005891","DOI":"10.1371\/journal.ppat.1005891","article-title":"Dysregulated TGF-\u03b2 production underlies the age-related vulnerability to chikungunya virus","volume":"12","author":"Uhrlaub","year":"2016","journal-title":"PLoS Pathog."},{"key":"ref142","first-page":"32","volume-title":"Quality systems approach to pharmaceutical current good manufacturing practice regulations, U.S. Department of Health and Human Services Food Drug Administration","year":"2006"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"812110","DOI":"10.3389\/fcell.2022.812110","article-title":"Synergistic effects of toll-like receptor 1\/2 and toll-like receptor 3 signaling triggering interleukin 27 gene expression in chikungunya virus-infected macrophages","volume":"10","author":"Vald\u00e9s-L\u00f3pez","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref144","volume-title":"VLA1553 \u2013 Valneva\u2019s single-shot chikungunya vaccine candidate","year":"2023"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/cells9040970","article-title":"Activation of the PI3K-AKT pathway by Old World alphaviruses","volume":"9","author":"Van Huizen","year":"2020","journal-title":"Cells"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/vaccines11061102","article-title":"An overview of Indian biomedical research on the chikungunya virus with particular reference to its Vaccine, an unmet medical need","volume":"11","author":"Varikkodan","year":"2023","journal-title":"Vaccine"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.7860\/jcdr\/2019\/42536.13335","article-title":"Seroprevalence of anti-chikungunya IgG antibodies among rheumatoid arthritis (RA) patients","author":"Verma","year":"2019","journal-title":"J. Clin. Diagn. Res."},{"key":"ref148","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/tropej\/fmv051","article-title":"Congenital chikungunya virus infection in Sincelejo, Colombia: A case series","volume":"61","author":"Villamil-G\u00f3mez","year":"2015","journal-title":"J. Trop. Pediatr."},{"key":"ref149","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"ref150","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1016\/j.ymthe.2021.05.018","article-title":"Live-attenuated RNA hybrid vaccine technology provides single-dose protection against chikungunya virus","volume":"29","author":"Voigt","year":"2021","journal-title":"Mol. Ther."},{"key":"ref151","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1128\/jvi.01603-09","article-title":"Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates","volume":"84","author":"Volk","year":"2010","journal-title":"J. Virol."},{"key":"ref152","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/infdis\/jiq006","article-title":"The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation","volume":"204","author":"Wauquier","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref153","doi-asserted-by":"publisher","first-page":"e0005318","DOI":"10.1371\/journal.pntd.0005318","article-title":"Identification of functional determinants in the chikungunya virus E2 protein","volume":"11","author":"Weber","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref154","doi-asserted-by":"publisher","first-page":"11644","DOI":"10.1128\/jvi.01432-14","article-title":"Reemergence of chikungunya virus","volume":"88","author":"Weibel Galluzzo","year":"2015","journal-title":"Rev. Med. Suisse"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ijid.2020.09.1278","article-title":"Temperature modulates innate immunity in Aedes aegypti during chikungunya virus infection","volume":"101","author":"Wimalasiri-Yapa","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref156","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1413250\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T05:29:35Z","timestamp":1721626175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1413250\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":154,"alternative-id":["10.3389\/fmicb.2024.1413250"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1413250","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1413250"}}